Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 88, 631-639
Abstract
No abstract availableKeywords
Funding Information
- Stanley Medical Research Institute (13T-012)
This publication has 73 references indexed in Scilit:
- Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implicationsNeuroscience, 2013
- TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanismsCell Death & Disease, 2011
- Inflammation-associated depression: From serotonin to kynureninePsychoneuroendocrinology, 2011
- Reconsidering anhedonia in depression: Lessons from translational neuroscienceNeuroscience & Biobehavioral Reviews, 2011
- Psychometric evaluation of the Snaith–Hamilton pleasure scale in adult outpatients with major depressive disorderInternational Clinical Psychopharmacology, 2010
- Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental DisordersAmerican Journal of Psychiatry, 2010
- Association of Anhedonia With Recurrent Major Adverse Cardiac Events and Mortality 1 Year After Acute Coronary SyndromeArchives of General Psychiatry, 2010
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009
- Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics, 2007